ALT Quote, Financials, Valuation and Earnings

Moderna has a net margin of -391500% compared to Altimmune's net margin of -907.48%. Altimmune's return on equity of -62.28% beat Moderna's return on equity of -29.23%.

Altimmune has a consensus price target of $17.60, signalling upside risk potential of 321.05%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Altimmune has higher upside potential than Moderna, analysts believe Altimmune is more attractive than Moderna.

Altimmune has a beta of 0.473, which suggesting that the stock is 52.709% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are smaller than Moderna quarterly revenues of $107M. Altimmune's net income of -$19.6M is higher than Moderna's net income of -$971M. Notably, Altimmune's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,089.22x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -391500% compared to Altimmune's net margin of --. Altimmune's return on equity of -62.28% beat Terns Pharmaceuticals's return on equity of --.

Altimmune has a consensus price target of $17.60, signalling upside risk potential of 321.05%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.14 which suggests that it could grow by 263.24%. Given that Altimmune has higher upside potential than Terns Pharmaceuticals, analysts believe Altimmune is more attractive than Terns Pharmaceuticals.

Altimmune has a beta of 0.473, which suggesting that the stock is 52.709% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Terns Pharmaceuticals quarterly revenues of --. Altimmune's net income of -$19.6M is higher than Terns Pharmaceuticals's net income of -$23.9M. Notably, Altimmune's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,089.22x versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -391500% compared to Altimmune's net margin of --. Altimmune's return on equity of -62.28% beat Viking Therapeutics's return on equity of --.

Altimmune has a consensus price target of $17.60, signalling upside risk potential of 321.05%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 185.37%. Given that Altimmune has higher upside potential than Viking Therapeutics, analysts believe Altimmune is more attractive than Viking Therapeutics.

Altimmune has a beta of 0.473, which suggesting that the stock is 52.709% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Viking Therapeutics quarterly revenues of --. Altimmune's net income of -$19.6M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Altimmune's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,089.22x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Y-mAbs Therapeutics has a net margin of -391500% compared to Altimmune's net margin of -24.86%. Altimmune's return on equity of -62.28% beat Y-mAbs Therapeutics's return on equity of -30.14%.

Altimmune has a consensus price target of $17.60, signalling upside risk potential of 321.05%. On the other hand Y-mAbs Therapeutics has an analysts' consensus of $14.70 which suggests that it could grow by 237.93%. Given that Altimmune has higher upside potential than Y-mAbs Therapeutics, analysts believe Altimmune is more attractive than Y-mAbs Therapeutics.

Altimmune has a beta of 0.473, which suggesting that the stock is 52.709% less volatile than S&P 500. In comparison Y-mAbs Therapeutics has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.403%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Y-mAbs Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Y-mAbs Therapeutics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are smaller than Y-mAbs Therapeutics quarterly revenues of $20.9M. Altimmune's net income of -$19.6M is lower than Y-mAbs Therapeutics's net income of -$5.2M. Notably, Altimmune's price-to-earnings ratio is -- while Y-mAbs Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,089.22x versus 2.19x for Y-mAbs Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.